Oncocytic lipoadenoma is a rare tumor, with only 18 cases having been reported since the first in 1998. We encountered a case of oncocytic lipoadenoma presenting as a slowly growing parotid mass in a 71-year-old man. This tumor is characteristically comprised of a mixture of oncocytes and adipocytes. The present case is one of five reported cases of oncocytic lipoadenoma showing sebaceous differentiation. The results of immunohistochemical study with DOG1 antibody supported the origination of this tumor in the striated duct.
Citations
Citations to this article as recorded by
Oncocytic sialolipoma of parotid gland: Case report and literature review VenuPatel Sureja, KoyyeRavindranath Tagore Indian Journal of Pathology and Microbiology.2023; 66(3): 591. CrossRef
Complex Component of Oncocytic and Non-Oncocytic Lipoadenomas in the Parotid Gland: A Case Report Fuyuki Sato, Takashi Nakajima, Takashi Sugino Diagnostics.2021; 11(8): 1478. CrossRef
Oncocyitic lipoadenoma of the parotid gland Renato PIANTANIDA, Alberto CARANTI, Adele CHIESA, Jessica BARIZZI, Ulrike PERRIARD, Filippo BARUCCA, Antonio PELLANDA Otorinolaringologia.2021;[Epub] CrossRef
A case of oncocytic lipoadenoma of the submandibular gland and its diagnostic cytology challenges Khaled A. Murshed, Ammar Khalafalla, Belal Alani, Hanan Farghaly, Moustafa Alkhalil Diagnostic Cytopathology.2020; 48(4): 364. CrossRef
An extremely rare case of giant oncocytic adenolipoma of the parotid gland Dipesh Shakya, Ajit Nepal Clinical Case Reports.2020; 8(12): 2390. CrossRef
A rare cause of primary hyperparathyroidism: Parathyroid lipoadenoma Sabri Özden, Servet Güreşci, Barış Saylam, Gül Dağlar Auris Nasus Larynx.2018; 45(6): 1245. CrossRef
Oncocytic osteolipoadenoma of the submandibular gland Domenico Corradi, Rodolfo Monaco, Giulia D'Angelo, Paola Bini, Teore Ferri, Enrico M Silini Histopathology.2016; 69(1): 148. CrossRef
BACKGROUND Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the gastrointestinal tract. Expression of KIT protein (CD117) is an important diagnostic criterion of GIST. However, about 5% of GISTs are CD117 negative. Discovered on GIST 1 (DOG1) was introduced recently as a promising marker for GIST. We tested this new antibody in 105 GISTs tissue specimens, including 6 cases of metastatic GISTs, to determine the usefulness of DOG1 expression in the diagnosis of GISTs. METHODS We performed immunohistochemical (IHC) staining for DOG1 and CD117 on tissue microarrays that included 70 gastric GISTs, 29 small intestinal GISTs, 6 metastatic GISTs, 14 gastric leiomyomas and 16 gastric schwannomas. RESULTS DOG1 was positive in 98.1% (103/105) of GISTs and CD117 was positive in 97.1% (102/105) of GISTs. Only 1 case was negative for both markers. Two (66.7%) out of 3 GISTs tested CD117 negative were tested DOG1 positive. All leiomyomas and schwannomas were negative for both DOG1 and CD117. CONCLUSIONS DOG1 was highly expressed in GIST including CD117 negative cases. Adding DOG1 testing to the IHC panel for diagnosing GIST will help to identify GIST patients who are CD117 negative but may otherwise benefit from targeted therapy.
Citations
Citations to this article as recorded by
Gastrointestinal tract spindle cell tumors with interstitial cells of Cajal: Prevalence excluding gastrointestinal stromal tumors So Jung Lee, Chung Su Hwang, Ahrong Kim, Kyungbin Kim, Kyung Un Choi Oncology Letters.2016; 12(2): 1287. CrossRef